Novartis | NOVN - Capitaux D'Emprunt

Prix De L'Action
113.42
Variation Quotidienne
-1.30 -1.13%
Mensuellement
-5.34%
Annuel
20.93%
Q2 Prévisions
111.47




Capitaux D'Emprunt Changement Date
AbbVie USD 62.97B 12M 2025-09
Alcon AG USD 4.59B 0 2025-12
Almirall EUR 324.81M 61.32M 2025-12
Amgen USD 50B 2.43B 2025-12
AstraZeneca USD 26.14B 19.58B 2025-12
Autolus Therapeutics Ltd USD 251.94M 7.31M 2025-09
Bayer EUR 31.83B 877M 2025-12
Biogen USD 6.29B 1.4M 2025-09
Bristol-Myers Squibb USD 42.85B 1.62B 2025-12
Eli Lilly USD 40.87B 5.6M 2025-12
Fresenius EUR 10.8B 1.49B 2025-09
Fresenius Medical Care EUR 4.85B 4.49B 2025-12
Galapagos EUR 5.19M 574K 2025-12
Genmab DKK 5.14B 5.01B 2025-12
Gilead Sciences USD 22.13B 6M 2025-12
GlaxoSmithKline GBP 14.71B 186M 2025-12
GRIFOLS EUR 8.47B 624.81M 2025-12
Hikma Pharmaceutical USD 1.49B 692M 2025-12
J&J USD 37.53B 1.91B 2026-03
Lonza CHF 3.88B 323M 2025-12
Merck EUR 10.73B 277M 2025-12
Merck USD 39.97B 6B 2025-09
Novartis USD 29.59B 5.35B 2025-12
Novartis USD 29.59B 5.35B 2025-12
Novo Nordisk DKK 118.94B 29.76B 2025-12
Orion EUR 110.6M 4.7M 2026-03
Pfizer USD 57.41B 93M 2025-09
Philips EUR 6.93B 303M 2025-12
Recordati EUR 2.18B 89.51M 2025-09
Regeneron Pharmaceuticals USD 2.71B 720.4M 2025-12
Roche Holding CHF 27.43B 966M 2025-12
Sanofi EUR 13.84B 1.88B 2026-03
UCB EUR 2.18B 634M 2025-12